BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28066353)

  • 1. APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms.
    Okada A; Iwatani Y
    Front Microbiol; 2016; 7():2027. PubMed ID: 28066353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    Soros VB; Yonemoto W; Greene WC
    PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G.
    Morse M; Huo R; Feng Y; Rouzina I; Chelico L; Williams MC
    Nat Commun; 2017 Sep; 8(1):597. PubMed ID: 28928403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family.
    Imahashi M; Nakashima M; Iwatani Y
    Front Microbiol; 2012; 3():250. PubMed ID: 22787460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
    Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
    Fan B; Cen S; Jiang JD
    Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
    Mbisa JL; Barr R; Thomas JA; Vandegraaff N; Dorweiler IJ; Svarovskaia ES; Brown WL; Mansky LM; Gorelick RJ; Harris RS; Engelman A; Pathak VK
    J Virol; 2007 Jul; 81(13):7099-110. PubMed ID: 17428871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replication protein A (RPA) hampers the processive action of APOBEC3G cytosine deaminase on single-stranded DNA.
    Lada AG; Waisertreiger IS; Grabow CE; Prakash A; Borgstahl GE; Rogozin IB; Pavlov YI
    PLoS One; 2011; 6(9):e24848. PubMed ID: 21935481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Antiviral Innate Immunity Through APOBEC Ribonucleoprotein Complexes.
    Salter JD; Polevoda B; Bennett RP; Smith HC
    Subcell Biochem; 2019; 93():193-219. PubMed ID: 31939152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
    Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
    Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategy of Human Cytomegalovirus To Escape Interferon Beta-Induced APOBEC3G Editing Activity.
    Pautasso S; Galitska G; Dell'Oste V; Biolatti M; Cagliani R; Forni D; De Andrea M; Gariglio M; Sironi M; Landolfo S
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repair of APOBEC3G-Mutated Retroviral DNA
    Salas-Briceno K; Ross SR
    J Virol; 2021 Oct; 95(22):e0124421. PubMed ID: 34468176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of APOBEC3G activity impedes double-stranded DNA repair.
    Prabhu P; Shandilya SM; Britan-Rosich E; Nagler A; Schiffer CA; Kotler M
    FEBS J; 2016 Jan; 283(1):112-29. PubMed ID: 26460502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.